US Stem Cell Stock

US Stem Cell ROE

The Return on Equity (ROE) of US Stem Cell (USRM) as of Aug 12, 2026 is 19.38 %. In the previous year, Return on Equity (ROE) was 25.75 % — a change of -24.73% (lower).

ROE

19.38 %

YoY

-24.73%

Last updated:

In 2026, US Stem Cell's return on equity (ROE) was 19.38 %, a -24.73% increase from the 25.75 % ROE in the previous year.

Access this data via the Eulerpool API

US Stem Cell Stock analysis

What does US Stem Cell do? US Stem Cell Inc is a company specializing in the field of regenerative medicine. It was founded in 1999 and is headquartered in Sunrise, Florida. The company has experienced rapid development in recent years and is one of the leading providers of stem cell therapies in the USA. The business model of US Stem Cell is based on the development and marketing of stem cell products and therapies that are intended to help patients improve their health and treat diseases. The company focuses on a range of therapeutic applications, such as the treatment of degenerative diseases, injuries, and chronic pain. US Stem Cell operates several divisions, including the Cell Processing and Storage Center, which specializes in the processing and storage of stem cells. The company also has its own research and development team that develops products and therapies and subjects them to clinical trials. US Stem Cell offers various products and therapies, including autologous stem cell therapy. In this treatment, stem cells are taken from the patient's own body, processed, and then used at the affected site. This is intended to aid in the regeneration of damaged tissue and reduce inflammation in the body. Another treatment method is the use of exogenous stem cells sourced from other donors. US Stem Cell has also entered into a partnership with the Advanced Regenerative Manufacturing Institute (ARMI) to research and develop technology for the production of biological materials and tissues. This collaboration aims to increase the availability of stem cell therapies and advance research in this field. US Stem Cell has experienced some controversies in recent years, particularly related to the use of inappropriate protocols and the performance of stem cell therapies without sufficient scientific evidence. However, the company has emphasized that their therapies are based on scientific knowledge and rigorous protocols, and that they work closely with medical professionals to ensure the safety and efficacy of their treatments. Overall, US Stem Cell Inc has established itself as a significant player in the field of regenerative medicine, particularly in the area of stem cell therapy. The company is committed to developing new therapies that help patients improve their quality of life and treat diseases. Despite some controversies, US Stem Cell remains an important and promising company in the biotechnology industry. US Stem Cell is one of the most popular companies on Eulerpool.

ROE Details

Decoding US Stem Cell's Return on Equity (ROE)

US Stem Cell's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing US Stem Cell's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

US Stem Cell's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in US Stem Cell’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about US Stem Cell stock

Return on Equity (ROE) of US Stem Cell is 19.38 % in 2026.

Return on Equity (ROE) of US Stem Cell changed from 25.75 % to 19.38 %, representing a -24.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) US Stem Cell since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s US Stem Cell with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — US Stem Cell

All Key Metrics — US Stem Cell